跳至主要内容
临床试验/NL-OMON21497
NL-OMON21497招募中不适用

A randomized phase II study of doxorubicin combined with thalidomide versus doxorubicin alone for patients with unresectable hepatocellular carcinoma.

ot applicable0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
ot applicable
入组人数
30

研究概览

简要总结

/A

研究设计

研究类型
Interventional

入排标准

入选标准

  • Histologically proven HCC, irresectable tumor, failure to previous treatment, WHO 0-2, at least 4 weeks since prior treatment with HMG-Coa reductase inhibitors or systemic immunosuppresiva, adequate hepatic and bone marrow function.

排除标准

  • Prior treatment with doxorubicin or thalidomide, uncontrolled hypertension, unstable angina, arrhythmias requiring treatment, MI, thrombo-embolic events requiring treatment, congestive heartfailure or cardiomyopathy requiring treatment, peripheral neuropathy.

研究者

发起方
ot applicable

相似试验

已完成
不适用
A randomised phase II study of doxorubicin combined with thalidomide versus doxorubicin alone for patients with unresectable hepatocellular carcinomaCancer
ISRCTN53872240Erasmus Medical Centre (Netherlands)30
已完成
2 期
Treatment With Pazopanib for Neoadjuvant Breast CancerNeoplasms, Breast
NCT00849472GlaxoSmithKline101
Unknown
2 期
Randomized Study of Doxorubicin and Cyclophosphamide With or Without Intermittent Sunitinib in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer Patients With Measurable Primary Breast TumorBreast Cancer
NCT01176799National University Hospital, Singapore73
进行中(未招募)
不适用
A Randomized Phase 2 Trial of Doxorubicin plus Pemetrexed followed by Docetaxel, versus Doxorubicin plus Cyclophosphamide followed by Docetaxel, as Neoadjuvant Treatment for Early Breast Cancereoadjuvant chemotherapy in operable breast cancerMedDRA version: 14.1Level: PTClassification code 10057654Term: Breast cancer femaleSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2005-000021-32-ITELI LILLY256
进行中(未招募)
1 期
A Randomized Phase 2 Trial of Doxorubicin plus Pemetrexed followed by Docetaxel, versus Doxorubicin plus Cyclophosphamide followed by Docetaxel, as Neoadjuvant Treatment for Early Breast Cancer - N/AFemales with histologically confirmed diagnosis of primary early breast cancer, with a tumor size = 2 cm, of Stages T2-T4/N0-2/, as confirmed by incisional or core biopsy M0 will be treated with chemotherapy prior to surgery..
EUCTR2005-000021-32-ESilly S.A.256
A randomized phase II study of doxorubicin combined... | 临床试验